# RANDOMIZED CLINICAL TRIAL OF ASPIRIN AS PROPHYLAXIS FOR THROMBOEMBOLISM IN HIP ARTHROPLASTY

## TL;DR

This clinical trial compared 200 mg and 600 mg aspirin to prevent blood clots after hip replacement surgery, finding no significant difference between the doses.

## Contribution

The study demonstrates that low-dose aspirin (200 mg) is as effective as higher doses in preventing thrombosis after hip arthroplasty.

## Key findings

- No significant difference in thrombus occurrence between 200 mg and 600 mg aspirin groups.
- All detected thrombi were asymptomatic and did not require additional treatment.
- Low-dose aspirin did not cause significant bleeding or hematological changes.

## Abstract

This study aims to evaluate aspirin as a chemical prophylaxis (200 mg) in total hip arthroplasty.

the study compared two groups and used ultrasonography (USG) to screen for low-deep venous thrombosis. Group 1 received 600 mg (control), and Group 2 received 200 mg of (intervention), associated with the use of elastic compression stockings and early walking

fourteen patients were allocated to Group A (200mg), and 16 to Group B (600mg); in group A (200mg), 3 cases with thrombus below the popliteal vein were detected at the first USG examination. All of them are in the left lower limb (21.4%). In group B (600 mg), 5 cases were identified after the first exam (31.2%). All cases were asymptomatic and followed the protocol with prophylaxis only with Aspirin.

In the statistical data, there were no differences in the presence of thrombus between the 200- and 600 mg groups, which is credited to using low-dose aspirin in low doses (200mg). Hematimetric levels returned to baseline levels and suggested there was no chronic or acute bleeding related to the use of aspirin. The manuscript was prepared according to the CONSORT guideline 2010.
Level of Evidence I; Longitudinal Randomized Comparative Clinical Study
.